Burke Chloe, Freeman Tom P, Sallis Hannah, Wootton Robyn E, Burnley Annabel, Lange Jonas, Lees Rachel, Sawyer Katherine, Taylor Gemma M J
Department of Psychology, University of Bath, Bath, UK.
School of Psychological Science, University of Bristol, Bristol, UK.
Psychol Med. 2024 Dec 2;54(15):1-15. doi: 10.1017/S0033291724002587.
Observational studies consistently report associations between tobacco use, cannabis use and mental illness. However, the extent to which this association reflects an increased risk of new-onset mental illness is unclear and may be biased by unmeasured confounding.
A systematic review and meta-analysis (CRD42021243903). Electronic databases were searched until November 2022. Longitudinal studies in general population samples assessing tobacco and/or cannabis use and reporting the association (e.g. risk ratio [RR]) with incident anxiety, mood, or psychotic disorders were included. Estimates were combined using random-effects meta-analyses. Bias was explored using a modified Newcastle-Ottawa Scale, confounder matrix, -values, and Doi plots.
Seventy-five studies were included. Tobacco use was associated with mood disorders ( = 43; RR: 1.39, 95% confidence interval [CI] 1.30-1.47), but not anxiety disorders ( = 7; RR: 1.21, 95% CI 0.87-1.68) and evidence for psychotic disorders was influenced by treatment of outliers ( = 4, RR: 3.45, 95% CI 2.63-4.53; = 5, RR: 2.06, 95% CI 0.98-4.29). Cannabis use was associated with psychotic disorders ( = 4; RR: 3.19, 95% CI 2.07-4.90), but not mood ( = 7; RR: 1.31, 95% CI 0.92-1.86) or anxiety disorders ( = 7; RR: 1.10, 95% CI 0.99-1.22). Confounder matrices and -values suggested potential overestimation of effects. Only 27% of studies were rated as high quality.
Both substances were associated with psychotic disorders and tobacco use was associated with mood disorders. There was no clear evidence of an association between cannabis use and mood or anxiety disorders. Limited high-quality studies underscore the need for future research using robust causal inference approaches (e.g. evidence triangulation).
观察性研究一致报告了烟草使用、大麻使用与精神疾病之间的关联。然而,这种关联在多大程度上反映了新发精神疾病风险的增加尚不清楚,并且可能受到未测量的混杂因素的影响。
一项系统评价和荟萃分析(CRD42021243903)。检索电子数据库直至2022年11月。纳入在一般人群样本中评估烟草和/或大麻使用情况,并报告与焦虑症、情绪障碍或精神病性障碍的关联(如风险比[RR])的纵向研究。使用随机效应荟萃分析合并估计值。使用改良的纽卡斯尔-渥太华量表、混杂因素矩阵、P值和Doi图探讨偏倚。
纳入75项研究。烟草使用与情绪障碍相关(n = 43;RR:1.39,95%置信区间[CI]为1.30 - 1.47),但与焦虑症无关(n = 7;RR:1.21,95%CI为0.87 - 1.68),并且精神病性障碍的证据受到异常值处理的影响(n = 4,RR:3.45,95%CI为2.63 - 4.53;n = 5,RR:2.06,95%CI为0.98 - 4.29)。大麻使用与精神病性障碍相关(n = 4;RR:3.19,95%CI为2.07 - 4.90),但与情绪障碍(n = 7;RR:1.31,95%CI为0.92 - 1.86)或焦虑症(n = 7;RR:1.10,95%CI为0.99 - 1.22)无关。混杂因素矩阵和P值表明可能高估了效应。只有27%的研究被评为高质量。
两种物质均与精神病性障碍相关,烟草使用与情绪障碍相关。没有明确证据表明大麻使用与情绪或焦虑症之间存在关联。有限的高质量研究强调了未来使用稳健的因果推断方法(如证据三角法)进行研究的必要性。